Iris Nakamura
Biohacking Correspondent
Biohackers and the quantified-self crowd
Iris Nakamura covers the biohacking and quantified-self frontier — wearables, continuous monitoring, peptides and protocols — with a reporter's eye for which gadgets and claims the data actually supports.
Latest articles
GLP-1 Showdown: Tirzepatide, Semaglutide, and a New Weekly Contender
A network meta-analysis finally ranks the incretin heavyweights head-to-head, while a novel once-weekly peptide files its first big numbers. Here's what the data actually shows.
Tirzepatide's Expanding Frontier: From Pediatric Diabetes to Liver Mitochondria
A landmark phase 3 trial puts the dual-receptor agonist on the map for adolescents with type 2 diabetes — and new mechanistic work suggests its effects reach all the way down to the mitochondrion.
Orforglipron and the GLP-1 Era: Oral Pills, Reproductive-Age Prescribing, and the Algorithm Selling Them
The first non-peptide oral GLP-1 has real bioavailability data, prescriptions to women of reproductive age are climbing fast, and social-media ads are quietly rewriting how the public reads the science.
GLP-1 Receptor Agonists in 2026: Beyond Semaglutide to the Next Generation
A wave of head-to-head trials and a biased-agonist newcomer show the GLP-1 class is fragmenting into distinct molecules with measurably different profiles.
The Next GLP-1: Orforglipron Brings Pill-Form, Non-Peptide Receptor Agonism
A 26-week Phase 2 trial pits a once-daily oral non-peptide against dulaglutide — and the β-cell and insulin-sensitivity signals are hard to ignore.
Semaglutide's Expanding Reach: From Waistlines to Kidneys, Liver, and Brain
GLP-1 receptor agonists keep finding new organs to help. A fresh slate of 2025 evidence maps where the signal is strongest — and where it's still preliminary.
GLP-1s Beyond Glucose: Liver, Plaque, and a Pancreas Warning Shot
Semaglutide, exendin-4, and tirzepatide are pushing GLP-1 receptor agonists into hepatology and cardiology — while a fresh case report reminds us the safety ledger is still open.
Beyond Weight Loss: GLP-1 Agonists Push Into Addiction Medicine and Vascular Repair
Semaglutide and liraglutide are being studied well past their metabolic origins. Early signals point to alcohol use disorder and diabetic blood-vessel protection — but the evidence is still uneven.
Telemedicine's Quiet Cost: When Virtual Visits Skip the Screening Conversation
New Israeli data suggest that patients seen mostly through telemedicine end up with a different preventive-care footprint than those seen in person — a structural blind spot worth watching.
Bone Health Before Spine Surgery: Which Anabolic Drugs Actually Move the Needle?
A single-institution analysis used CT-derived Hounsfield Units to compare modern osteoporosis drugs in preoperative patients. The signal is real but moderate — and frailty quietly blunts the response.
The Next GLP-1 Frontier: Oral Pills, Muscle Loss, and the Mind
As the GLP-1 class expands beyond weekly injections, three new studies sketch a more complicated risk-benefit map than the headline weight-loss numbers suggest.
The Quiet Risk in the Peptide Boom: Immunogenicity and What Compounding Pharmacies Don't Test For
Synthetic peptides now account for more than 1 in 10 new FDA-approved chemical entities. The frontier safety question isn't potency — it's what your immune system makes of the molecule, and the impurities riding alongside it.